Zacks: Brokerages Expect American Renal Associates Holdings Inc (NYSE:ARA) to Announce -$0.09 EPS

Share on StockTwits

Wall Street brokerages expect American Renal Associates Holdings Inc (NYSE:ARA) to announce ($0.09) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for American Renal Associates’ earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.04). The firm is expected to report its next quarterly earnings report on Tuesday, February 4th.

On average, analysts expect that American Renal Associates will report full-year earnings of $0.03 per share for the current fiscal year. For the next year, analysts expect that the company will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.49) to ($0.28). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow American Renal Associates.

American Renal Associates (NYSE:ARA) last posted its earnings results on Tuesday, November 5th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.37. American Renal Associates had a positive return on equity of 23.16% and a negative net margin of 1.75%. The firm had revenue of $211.43 million for the quarter, compared to analyst estimates of $215.06 million.

Several research firms have commented on ARA. Zacks Investment Research downgraded American Renal Associates from a “hold” rating to a “sell” rating in a research note on Monday, January 6th. SunTrust Banks upped their price objective on American Renal Associates from $9.00 to $11.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. ValuEngine downgraded American Renal Associates from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, Deutsche Bank began coverage on American Renal Associates in a research note on Friday, January 3rd. They set a “hold” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $11.00.

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its stake in shares of American Renal Associates by 28.7% during the 2nd quarter. BlackRock Inc. now owns 1,196,668 shares of the company’s stock worth $8,904,000 after purchasing an additional 266,776 shares during the period. Renaissance Technologies LLC increased its holdings in American Renal Associates by 38.3% in the 2nd quarter. Renaissance Technologies LLC now owns 638,960 shares of the company’s stock valued at $4,754,000 after purchasing an additional 177,100 shares in the last quarter. State Street Corp increased its holdings in American Renal Associates by 42.1% in the 3rd quarter. State Street Corp now owns 306,227 shares of the company’s stock valued at $1,935,000 after purchasing an additional 90,762 shares in the last quarter. Northern Trust Corp grew its stake in shares of American Renal Associates by 2.5% during the second quarter. Northern Trust Corp now owns 175,543 shares of the company’s stock valued at $1,306,000 after acquiring an additional 4,314 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in American Renal Associates by 29.7% in the second quarter. Charles Schwab Investment Management Inc. now owns 103,891 shares of the company’s stock worth $773,000 after purchasing an additional 23,760 shares in the last quarter. 85.37% of the stock is currently owned by institutional investors.

Shares of ARA opened at $9.60 on Tuesday. The company has a debt-to-equity ratio of 8.05, a current ratio of 1.01 and a quick ratio of 0.97. American Renal Associates has a 12 month low of $5.48 and a 12 month high of $14.10. The stock’s 50 day moving average is $9.66 and its two-hundred day moving average is $8.05.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Read More: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.